| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Btk |
| Uniprot No | Q06187 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-659aa |
| 氨基酸序列 | MAAVILESIFLKRSQQKKKTSPLNFKKRLFLLTVHKLSYYEYDFERGRRG SKKGSIDVEKITCVETVVPEKNPPPERQIPRRGEESSEMEQISIIERFPY PFQVVYDEGPLYVFSPTEELRKRWIHQLKNVIRYNSDLVQKYHPCFWIDG QYLCCSQTAKNAMGCQILENRNGSLKPGSSHRKTKKPLPPTPEEDQILKK PLPPEPAAAPVSTSELKKVVALYDYMPMNANDLQLRKGDEYFILEESNLP WWRARDKNGQEGYIPSNYVTEAEDSIEMYEWYSKHMTRSQAEQLLKQEGK EGGFIVRDSSKAGKYTVSVFAKSTGDPQGVIRHYVVCSTPQSQYYLAEKH LFSTIPELINYHQHNSAGLISRLKYPVSQQNKNAPSTAGLGYGSWEIDPK DLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMM NLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLE MCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDE YTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYER FTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSN ILDVMDEES |
| 预测分子量 | 78 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Btk(Bruton's tyrosine kinase)重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**：*Expression and purification of soluble recombinant Bruton's tyrosine kinase in E. coli for biochemical studies*
**作者**：Mohamed, A.J. et al.
**摘要**：研究报道了在大肠杆菌中高效表达可溶性重组Btk蛋白的方法，通过优化诱导条件和融合标签设计，获得了具有激酶活性的Btk蛋白，适用于体外酶学分析和抑制剂筛选。
---
2. **文献名称**：*Structural basis of Btk PH-TH domain interaction with lipid membranes*
**作者**：Joseph, R.E. et al.
**摘要**：通过X射线晶体学和核磁共振技术解析了重组Btk蛋白的PH-TH结构域与脂质膜结合的分子机制，揭示了Btk在细胞膜定位中的关键构象变化。
---
3. **文献名称**：*Development of a high-throughput assay for Btk kinase activity using recombinant protein*
**作者**：Lou, Y. et al.
**摘要**：利用重组Btk激酶结构域建立了一种高通量荧光检测方法，用于筛选和评估Btk小分子抑制剂，为治疗B细胞恶性肿瘤和自身免疫疾病提供工具。
---
4. **文献名称**：*Functional characterization of Btk mutations in X-linked agammaglobulinemia using recombinant protein*
**作者**：Kanegane, H. et al.
**摘要**：通过表达携带不同突变的重组Btk蛋白，分析了X连锁无丙种球蛋白血症(XLA)患者中Btk激酶活性和稳定性的缺陷，揭示了突变与临床表型的关联。
---
这些文献涵盖了Btk重组蛋白的表达、结构解析、功能研究和应用开发，可根据需求进一步检索具体期刊及发表年份。
**Background of Btk Recombinant Protein**
Bruton's tyrosine kinase (Btk), a non-receptor cytoplasmic tyrosine kinase, plays a pivotal role in B-cell development, differentiation, and signaling. It belongs to the Tec kinase family and is critical for the B-cell receptor (BCR) signaling pathway, which regulates survival, proliferation, and antibody production in B-cells. Mutations in the *BTK* gene are linked to X-linked agammaglobulinemia (XLA), a primary immunodeficiency characterized by impaired B-cell maturation and reduced immunoglobulins.
Recombinant Btk protein is engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce functional or truncated forms of the kinase for research and therapeutic applications. This protein typically retains key domains, such as the pleckstrin homology (PH) domain for membrane targeting, the SH3/SH2 domains for protein interactions, and the catalytic kinase domain.
In drug discovery, recombinant Btk is widely utilized to study enzyme activity, screen inhibitors, and investigate molecular mechanisms underlying B-cell malignancies (e.g., chronic lymphocytic leukemia) and autoimmune disorders. Small-molecule Btk inhibitors, like ibrutinib, have revolutionized targeted therapies by covalently binding to the kinase domain, blocking aberrant signaling.
Additionally, recombinant Btk aids in structural studies (e.g., X-ray crystallography) to elucidate inhibitor-binding modes and resistance mutations. Its role extends to studying cross-talk with Toll-like receptor (TLR) and chemokine signaling pathways, highlighting broader immune regulatory functions.
Ongoing research focuses on optimizing recombinant Btk for high-throughput assays, understanding its role in non-B-cell contexts (e.g., myeloid cells), and developing next-generation inhibitors to address clinical resistance. This protein remains a cornerstone in both basic immunology and translational oncology.
×
